Search results for: Adrian Towse
Filter search results
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
…product will reach the market at all. Towse, A. and Garau, M. (2018). Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc Zamora, B.,…
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
22 January 2019
…Report, London: Office of Health Economics Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in…
OHE Response to Public Consultation on NICE Principles
7 February 2019
…pp.145-165. DOI. RePEc. Shah, K.K., 2017. Valuing Health at the End of Life. PhD thesis. Sheffield: University of Sheffield. Towse, A. and Garau, M., 2018. Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
…Development. This blog post has also been published on the Center for Global Development website. Chalkidou, K., Garau, M., Nemzoff,C., Rodes-Sanchez, M., Silverman, R., and Towse A. (2019). Blueprint for…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…to develop better technologies that deliver more health and economic gain. Chalkidou, K., Towse, A., Silverman, R., Garau, M., & Ramakrishnan, G. (2020). Market-driven, value-based, advance commitment (MVAC): accelerating the…
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
…value of a novel orphan medicine. Related research Towse, A. and Garau, M. (2018). Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc Garau,…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 April 2012
…of co-dependent technologies. A revised version of this paper has been published in Personalized Medicine and can be downloaded from: http://www.futuremedicine.com/doi/abs/10.2217/pme.12.99 Please cite as: Garau, M., Towse, A., Garrison, L.,…
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
…has been published in PharmacoEconomics and can be downloaded from: http://link.springer.com/article/10.1007%2Fs40273-012-0001-x Please cite as: Sussex, J., Towse, A. and Devlin, N., 2013. Operationalizing value-based pricing of medicines. PharmacoEconomics, 31(1), pp.1-10….
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
…and can be downloaded from: http://www.tandfonline.com/doi/abs/10.1080/13571516.2011.584434 Please cite as: Towse, A. and Sharma, P., 2011. Incentives for R&D for new antimicrobial drugs. International Journal of the Economics of Business, 18(2),…